Home

Julie Hambleton

CIK 1578771 · SVP, Chief Medical Officer · last filed 2026-06-29

Julie Hambleton is a SVP, Chief Medical Officer who has filed 40 SEC Form 4 insider transactions across 5 companies since 2014. The most recent filing, for ERAS, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$2.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $97.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$97.1K

Companies

5

Total Filings

40

Lifetime Open-Market Net

-$2.13M

Filer Profile

Reported Address
C/O FIVE PRIME THERAPEUTICS, INC.
TWO CORPORATE DRIVE
SOUTH SAN FRANCISCO, CA 94080
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ERAS Director 6,000 $16.19 $97.1K $96.0K 6 2026-06-29
IGM Biosciences, Inc. (IGMS) Delisted Director 0 $1.27 $0 -$360.3K 11 2025-08-14
SpringWorks Therapeutics, Inc. (SWTX) Delisted Director 0 $46.99 $0 -$1.09M 12 2025-07-02
IDYA SVP, Chief Medical Officer — $39.86 — $0 1 2020-02-25
FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted EVP & Chief Medical Officer 95,983 $38.00 $3.65M -$778.2K 6 2015-11-13

Recent Filings

40 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-29 ERAS Grant (A) — $0 EDGAR
2025-08-14 IGM Biosciences, Inc. (IGMS) Delisted Disp (D) −2,000 $0 EDGAR
2025-07-02 SpringWorks Therapeutics, Inc. (SWTX) Delisted Disp (D) −14,155 $0 EDGAR
2025-06-26 ERAS Grant (A) — $0 EDGAR
2025-05-15 SpringWorks Therapeutics, Inc. (SWTX) Delisted Grant (A) +10,060 $0 EDGAR
2025-02-12 SpringWorks Therapeutics, Inc. (SWTX) Delisted Mixed — -$285.7K EDGAR
2025-02-10 SpringWorks Therapeutics, Inc. (SWTX) Delisted Notice (144) −13,774 -$730.2K EDGAR
2024-07-29 IGM Biosciences, Inc. (IGMS) Delisted Mixed — -$190.8K EDGAR
2024-07-25 IGM Biosciences, Inc. (IGMS) Delisted Notice (144) −15,132 -$211.1K EDGAR
2024-06-21 ERAS Grant (A) — $0 EDGAR
Showing 1–10 of 40
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.